Lessening Organ Dysfunction With VITamin C (LOVIT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03680274|
Recruitment Status : Recruiting
First Posted : September 21, 2018
Last Update Posted : December 31, 2020
|Condition or disease||Intervention/treatment||Phase|
|Sepsis Vitamin C Intensive Care Unit COVID-19 Pandemic Coronavirus||Drug: Vitamin C Other: Control||Phase 3|
Background. The burden of sepsis is increasing worldwide. It is the cause of 8 million global deaths each year. Currently, treatment options are limited to antimicrobials and supportive care such as intravenous fluids, vasopressors, mechanical ventilation, and renal replacement therapy. In the absence of effective therapies specifically targeting the dysregulated immune response, prolonged use of these life-sustaining therapies can be debilitating. A growing body of evidence suggesting that vitamin C, an inexpensive and readily available intervention, is potentially lifesaving in sepsis. Intravenous vitamin C may be the first therapy to mitigate the dysregulated cascade of events that leads to sepsis. If proven effective, vitamin C could be used worldwide and drastically change outcomes in high- and low-income settings alike.
Objectives. To determine whether intravenous vitamin C, compared to placebo, reduces mortality and morbidity in sepsis (induced by bacterial and viral pathogens (as COVID-19)), and compare clinical and biochemical measures of organ dysfunction, and health-related quality of life (HRQoL) at 6 months. To ascertain the volume of distribution, clearance, and plasma concentration over a course of 96 hours of intravenous vitamin C 50 mg/kg of weight every 6 hours or matching placebo (pharmacokinetic (PK) substudy).
Methods. Patients will be randomly assigned to vitamin C (intravenous, 50 mg/kg every 6h) or placebo (0.9% NaCl or dextrose 5% in water) for 96 hours. Study personnel at the clinical sites will document the composite of death or persistent organ dysfunction at day 28. Daily assessments will occur for organ function, on days 1, 3, 7 for inflammation, infection, and endothelial injury biomarkers, at baseline for vitamin C level, and at 6 months for mortality and HRQoL. The LOVIT Trial will be conducted in adult general Canadian and international intensive care units. For the PK substudy: Blood samples will be drawn around the 6th dose (second dose on day 2) at time 0 and then after administration at times 1h, 2h, 4h and 6h (the 6h level will be immediately prior to the next dose). The PK substudy will be conducted with 100 participants in 3 of the 25 participating centers.
Relevance. In the context of increasing off-label use of vitamin C for sepsis and ongoing trials of vitamin C bundled with other pharmacological interventions, the LOVIT Trial will constitute a rigorous assessment of the effect of vitamin C monotherapy on patient-important outcomes.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||800 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Lessening Organ Dysfunction With VITamin C (LOVIT)|
|Actual Study Start Date :||November 8, 2018|
|Estimated Primary Completion Date :||December 31, 2021|
|Estimated Study Completion Date :||December 31, 2022|
Experimental: Vitamin C
Vitamin C: 50 mg/kg every 6 hours for 96 hours.
Drug: Vitamin C
Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
Other Name: Ascorbic acid
Placebo Comparator: Control
Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
- Number of deceased participants or with persistent organ dysfunction [ Time Frame: Both assessed at 28 days ]Defined as death or dependency on mechanical ventilation, renal replacement, or vasopressors
- Number of participants with persistent organ dysfunction-free days in intensive care unit [ Time Frame: Up to day 28 ]Persistent organ dysfunction-free days in intensive care unit
- Number of participants deceased at 6 months [ Time Frame: 6 months ]Mortality at 6 months
- Score of health related quality of life in 6-month survivors [ Time Frame: 6 months ]
Assessed by the questionnaire EuroQol-5D (EQ-5D-5L). The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.
- Global tissue dysoxia [ Time Frame: Days 1, 3, 7 ]Assessed by serum lactate concentration
- Organ function (including renal function) [ Time Frame: Days 1, 2, 3, 4, 7, 10, 14, 28 ]Assessed by the Sequential Organ Failure Assessment (SOFA) score. Used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on 6 different sub-scores, one each for the respiratory (PaO2/FiO2 mmHg), cardiovascular (mean arterial pressure OR administration of vasopressors required), hepatic (liver bilirubin (mg/dl) [μmol/L]), coagulation (platelets×103/µl), renal (kidneys creatinine (mg/dl) [μmol/L] (or urine output)) and neurological (Glasgow coma scale). The sub-score of eah system ranges from 0 (best) to +4 (worst).
- Rate of inflammation [ Time Frame: Days 1, 3, 7 ]Assessed by interleukin-1 beta (IL-1ß), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP)
- Rate of infection [ Time Frame: Days 1, 3, 7 ]Assessed by procalcitonin (PCT)
- Rate of endothelial injury [ Time Frame: Days 1, 3, 7 ]Assessed by thrombomodulin (TM) and angiopoietin-2 (ANG-2)
- Occurrence of stage 3 acute kidney injury [ Time Frame: Up to day 28 ]Assessed by KDIGO (Kidney Disease: Improving Global Outcomes) criteria
- Acute hemolysis [ Time Frame: Up to day 28 ]
- clinician judgment of hemolysis, as recorded in the chart, OR
hemoglobin drop of at least 25 g/L within 24 hours of a dose of investigational product PLUS 2 of the following:
- reticulocyte count >2 times upper limit of normal at clinical site lab;
- haptoglobin < lower limit of normal at clinical site lab;
- indirect (unconjugated) bilirubin >2 times upper limit of normal at clinical site lab;
- Lactate dehydrogenase (LDH) >2 times upper limit of normal at clinical site lab.
- hemoglobin < 75 g/L AND at least 2 of the above criteria AND requires 2 units of packed red blood cells
- Hypoglycemia [ Time Frame: During the time participants receive the 16 doses of the investigational product and the 7 days following the last dose ]Core lab-validated glucose level of less than 3.8 mmol/L
- Vitamin C volume of distribution [ Time Frame: 6th dose of vitamin C (second dose on day 2) at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy) ]Assessed by chromatography-tandem mass spectrometry
- Vitamin C clearance [ Time Frame: 6th dose of vitamin C (second dose on day 2) at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy) ]Assessed by chromatography-tandem mass spectrometry
- Vitamin C plasma concentration [ Time Frame: 6th dose of vitamin C (second dose on day 2) at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy) ]Assessed by chromatography-tandem mass spectrometry
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03680274
|Contact: Marie-Helene Masse||819-346-1110 ext firstname.lastname@example.org|
|Contact: Marie-Claude Battista, PhD||819-346-1110 ext email@example.com|
|Research Center of the CHUS||Recruiting|
|Sherbrooke, Quebec, Canada, J1H 5N4|
|Contact: Marie-Helene Masse 819-346-1110 ext 14173 firstname.lastname@example.org|
|Contact: Marie-Claude Battista, PhD 819-346-1110 ext 12480 email@example.com|
|Principal Investigator:||François Lamontagne, MD FRCPC MSc||Université de Sherbrooke and CIUSSS de l'Estrie - CHUS|
|Principal Investigator:||Neill Adhikari, MDCM FRCPC MSc||Sunnybrook Health Sciences Centre, University of Toronto|